InterMune Inc., the California based drug making company, recorded a phenomenal jump of 74% on Friday morning in NASDAQ Stock Market composite trading. The stock was trading at $22.83 at 1:10 p. m., increasing by 56% over the closing price of Thursday.

The growth in the stock price is reported the highest ever since going public in March 2000. The reason behind this amazing growth in the stock is the more favorable review of its experimental lung medicine, pirfenidone, by U. S. regulators.

Encouraged by the less critical review by FDA, the investors showed their confidence in the stock today.

Though, the Food and Drug Administration agency said on its website that it will review the drug again on Tuesday, the reaction from FDA is considered very soft. The investors and market analysts were expecting an extremely critical review because the drug, pirfenidone, has failed in one study earlier.

Pirfenidone is used to treat idiopathic pulmonary fibrosis, a condition that results from lung tissues becoming thick and scarred. InterMune is a small biotechnology company at the moment, but if pirfenidone wins approval from the Food and Drug Administration, it could make InterMune a good target for the big players in the market for takeover.